Three Facing Fraud Charges In Magellan Lead Test Debacle
The now-Meridian subsidiary’s former CEO, COO and regulatory affairs director reportedly delayed telling the FDA and the public about incorrect results obtained from Magellan’s LeadCare line of blood tests.
You may also be interested in...
It’s the third expansion for a high-risk class I recall of LeadCare II, LeadCare Plus and LeadCare Ultra Blood Lead Tests.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced March-April 2016.
NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.